Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Psychedelic Leader to Advance Mental Health in 2021 with Growth of Clinics, Lab and Partnerships

(Image via Numinus Wellness Inc.) In 2020, Health Canada began allowing select patients to take psilocybin for relief of end-of-life-distress. This was followed by a proposed regulation revision that could allow doctors to prescribe both psilocybin and MDMA for t...
Stockhouse Editorial | January 14, 2021 |

Why This Psychedelics Company is Focused on Weight Management

Psychedelics are transforming so many aspects of our everyday lives — from treating mental health conditions to weight management and obesity. Companies like NeonMind Biosciences ( CSE:NEON , OTCQB:NMDBD , Forum ) are at the forefront of this innovation ...
Jocelyn Aspa | May 4, 2022 |

Anixa Licenses Another Potential Blockbuster

In January we proclaimed Anixa Biosciences Inc. (ANIX:NASDAQ) to be Tailwinds' stock of the year. This designation was awarded due to potential major milestones in both the detection and the curing of cancer. With its Cchek prostate diagnostic shooting for CLIA approval...
Streetwise Reports | July 25, 2019 |

A Revolution in Healthcare. A Transformative Investment Opportunity.

(Click image to play video) While the global COVID-19 pandemic has wreaked havoc on health and humanity over the past 12-month-plus, it has also invited a host of creative and innovative solutions to meet the needs of people who require a medical attention witho...
Dave Jackson | April 9, 2021 |

The Company that’s Delivering Medicalized Ibogaine-Centered Addiction Care

Universal Ibogaine Inc. (UI) ( TSX-V.IBO , Forum ) is a company uniquely-positioned to address the opioid epidemic through a safe, effective, and proven plant medicine – Ibogaine – and a proven treatment protocol which has successfully treated thousands of patients. ...
Dave Jackson | January 21, 2022 |

Ibogaine Drug Development: Creating The Gold Standard For Addiction Treatment

(Click image to play video.) A renewed interest in the therapeutic power psychedelic of compounds is revealing a potent and commercially viable solution. Vancouver BC-based Universal Ibogaine Inc. (UI) ( TSX-V: IBO , Forum ) is positioned to address the opioid e...
Dave Jackson | October 26, 2021 |

A Company on a Mission to Revolutionize Mental Healthcare. Here’s How.

When Stockhouse Editorial last caught up with Cybin Inc. ( NEO.CYBN , NYSE: CYBIN , Forum ) back in October, our audience learned about a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discover...
Dave Jackson | January 31, 2022 |

Numinus Wellness: The mental health business is estimated to grow to $530 billion by 2030

Numinus Wellness is in the business of psychedelic medicine but, more importantly, the mental health business. The mental health business is a sector that will be worth an estimated $530 billion dollars by the year 2030. Numinus has already seen more than a 618% ...
Brieanna McCutcheon | January 30, 2023 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

CloudMD Is My TeleHealth Stock

An entirely new—and highly profitable—industry is being borne out in 2020— TeleHealth. CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE) is my favorite way to play teleHealth. It's growing quickly with over 100,000 patients registered on its ap...
Streetwise Reports | April 29, 2020 |
1 2 3 4 5 6 7